Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.

Abstract

INTRODUCTION:

We studied the effect of dutasteride on bone mineral density (BMD) in aging male patients with lower urinary tract symptoms (LUTS) and prostatic enlargement.

METHODS:

We prospectively studied 17 patients with LUTS and prostatic enlargement. Before and 1 year after dutasteride (0.5 mg daily), we assessed International Prostate Symptom Score (IPSS), prostatic volume (PV), serum prostatic-specific antigen (PSA) and testosterone. BMD in the lumbar and femur was measured by DEXA method.

RESULTS:

Dutasteride significantly reduced PV (from 51 ± 24 to 34 ± 17 ml, p < 0.001) and improved IPSS (from 15.1 ± 9.8 to 11.7 ± 10.3, p < 0.05). Serum PSA was significantly decreased (from 3.2 ± 2.6 to 1.0 ± 0.8 ng/ml, p < 0.001), while serum testosterone "was not changed" significantly. BMD of the lumbar "was not changed" significantly after dutasteride. BMD of the femur was significantly improved (from 0.75 ± 0.14 to 0.82 ± 0.16 g/cm(2), p < 0.01). In nine patients whose testosterone was increased after dutasteride, BMD of the lumbar (from 1.18 ± 0.26 to 1.22 ± 0.25 g/cm(2), p < 0.05) and femur (from 0.76 ± 0.12 to 0.84 ± 0.16 g/cm(2), p < 0.05) was significantly improved.

CONCLUSIONS:

Dutasteride has a potential to improve BMD with elevation of serum testosterone in aging male patients with LUTS and prostatic enlargement.

• Authors: Naoki Wada, Kazumi Hashizume, Seiji Matsumoto, Hidehiro Kakizaki
• Journal: The aging male : the official journal of the International Society for the Study of the Aging Male (Aging Male) Vol. 19 Issue 1 Pg. 12-4 ( 2016) ISSN: 1473-0790 [Electronic] England
• PMID: 26225793 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• 5-alpha Reductase Inhibitors
• Testosterone
• Prostate-Specific Antigen
• Dutasteride

Topics

• 5-alpha Reductase Inhibitors (therapeutic use)
• Aged
• Aged, 80 and over
• Bone Density (drug effects)
• Dutasteride (therapeutic use)
• Humans
• Lower Urinary Tract Symptoms (drug therapy)
• Male
• Middle Aged
• Organ Size (drug effects)
• Pilot Projects
• Prospective Studies
• Prostate (drug effects, pathology)
• Prostate-Specific Antigen (blood)
• Prostatic Hyperplasia (diet therapy, pathology)
• Testosterone